Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)

NCT07136545 is registered in ClinicalTrials.gov with Taipei Veterans General Hospital, Taiwan as lead sponsor.

NCT NCT07136545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07136545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
Lead sponsor
Taipei Veterans General Hospital, Taiwan
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 13, 2025
Completion date
December 31, 2026
Enrollment
50 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc